2026-09-04Screening report
Data as of 2026-09-04US market
Summary
September 2026 equity research screening reveals deep valuation dislocations in high-FCF compounders including PayPal, CVS Health, Autodesk, Disney, and Alphabet.
Screening weights
Fundamental improvement30%
Candidate comparison
| Rank | Ticker | Sector | 3M return | Revenue YoY | OPM Δ | FCF | Score |
|---|
| 1 | PayPal Holdings, Inc. | Fintech / Payments | -12.5% | +10.0% | +1.2%p | TTM FCF $5.8B (+179% YoY Q2) | 88.0 |
| 2 | CVS Health Corporation | Healthcare Services / Pharmacy | -5.8% | +7.3% | +1.0%p | FY26 CFFO >=$11.5B (TTM FCF $8.3B) | 85.0 |
| 3 | Autodesk, Inc. | Enterprise Software / Design | -4.2% | +16.0% | +2.0%p | FY27 FCF $2.74B (Q2 FCF $561M) | 84.0 |
| 4 | The Walt Disney Company | Entertainment / Streaming | -2.1% | +7.0% | +1.9%p | Q3 FCF $3.1B (+63% YoY) | 82.0 |
| 5 | Alphabet Inc. | Technology / Digital Ads & Cloud | -14.8% | +24.2% | +2.0%p | TTM FCF $68.2B | 82.0 |
| 6 | Bristol-Myers Squibb | Healthcare / Biopharma | +18.2% | +6.0% | +3.2%p | TTM FCF $11.8B | 79.0 |
| 7 | United Parcel Service | Industrials / Logistics | -2.0% | +6.5% | +0.6%p | TTM FCF $4.8B | 77.5 |
| 8 | Salesforce, Inc. | Enterprise Cloud / CRM | +9.5% | +11.2% | +1.6%p | TTM FCF $12.8B (+22% YoY) | 76.5 |
| 9 | Archer-Daniels-Midland | Consumer Staples / Agribusiness | +1.9% | +7.2% | +2.5%p | TTM FCF $2.9B | 75.0 |
| 10 | Nike, Inc. | Consumer Discretionary / Footwear | -18.2% | -1.0% | +0.0%p | FY26 FCF $2.2B | 73.5 |
| 11 | Starbucks Corporation | Consumer Discretionary / Restaurants | +12.4% | -1.0% | +4.3%p | TTM FCF $3.8B | 72.0 |
| 12 | Amgen Inc. | Healthcare / Biotechnology | +27.6% | +10.0% | -0.5%p | Q2 FCF $3.5B (TTM FCF $10.5B) | 71.0 |
Screened names (observations)
Observation
Trading at ~10.0x forward P/E despite +10% YoY revenue growth, +179% Q2 FCF surge, and high-ROI buybacks retiring >7% of shares outstanding annually.
Catalysts to watch
- Fastlane guest checkout commercial scaling across major e-commerce platforms
- Venmo monetization acceleration via debit card volume and merchant checkout
- $5.0B-$6.0B annual share repurchases providing EPS accretion
Risks
- Competitive encroachment from Apple Pay and Google Wallet on mobile web checkout
- Margin mix compression from unbranded Braintree processing volume
Framework exit signals
- Transaction margin dollar growth turns negative for two consecutive quarters
- Branded checkout TPV growth decelerates below +2.0% YoY
Metrics to watch
- Branded checkout TPV growth YoY
- Transaction margin dollar growth rate
- Fastlane merchant adoption and conversion uplift
Observation
Deep value play at 11.7x forward P/E and 2.7%+ yield with structural margin turnaround underway (Medical Benefit Ratio improved 250 bps YoY to 87.4%).
Catalysts to watch
- Continued execution of Medicare Advantage margin recovery roadmap into FY2027
- AI-powered claims processing rollout through Aetna Claims Assist
- GLP-1 clinic and virtual care integration driving pharmacy foot traffic
Risks
- Potential medical utilization spikes in Medicare Advantage during H2 2026
- FTC and congressional legislative scrutiny on PBM rebate structures
Framework exit signals
- Medical Benefit Ratio (MBR) reverts above 89.5% for two consecutive quarters
- Caremark adjusted operating margin compresses by >100 bps YoY
Metrics to watch
- Health Care Benefits Medical Benefit Ratio (MBR)
- Health Care Benefits Adjusted Operating Income
- Total Medical Membership retention
Observation
Irreplaceable design software monopoly in AECO and manufacturing with 90%+ gross margins and 41% operating margins, trading at a 25% discount to historical multiples (~20.6x forward P/E).
Catalysts to watch
- Global completion of direct agency New Transaction Model eliminating multi-year discounting drag
- Monetization of generative AI design agents across Autodesk Forma, Fusion, and Revit
- Cross-selling operational workflows via MaintainX acquisition
Risks
- Temporary sales cycle elongation during the agency transition
- Cyclical macro slowdown in commercial construction starts
Framework exit signals
- Annual billings growth falling below +5.0% YoY
- Current Remaining Performance Obligations (cRPO) decelerating below +6.0% YoY
Metrics to watch
- cRPO constant-currency growth rate
- Billings growth
- Free cash flow conversion
Observation
Streaming profitability inflecting (+64% YoY Entertainment operating income) and high-barrier Experiences moat generating $10B+ quarterly cash flow, enabling $9B+ in share repurchases.
Catalysts to watch
- DTC streaming segment operating margin expansion toward 10%+
- Launch of standalone ESPN direct-to-consumer flagship platform
- $9.0B+ share buyback execution in FY2026
Risks
- Linear TV cord-cutting accelerating faster than DTC pricing gains
- Consumer discretionary spending softening at domestic theme parks
Framework exit signals
- DTC streaming segment relapsing into quarterly operating losses
- Experiences segment revenue growth decelerating below +2.0% YoY
Metrics to watch
- DTC Streaming Segment Operating Income
- Experiences segment revenue and operating margin
- Free cash flow generation
Observation
Mega-cap value dislocation at ~16.2x forward P/E with +24% consolidated revenue growth and Google Cloud revenue accelerating +82% YoY.
Catalysts to watch
- Antitrust regulatory clarity and search remedy settlement without structural breakup
- Gemini OS native AI integration across Android and Google Workspace
- Google Cloud operating margin scaling as custom TPU silicon lowers inferencing unit costs
Risks
- DOJ antitrust remedies impacting exclusive search default distribution
- Elevated infrastructure depreciation from heavy AI CapEx cycles
Framework exit signals
- Core Search & Other revenue growth decelerating below +4.0% YoY
- Google Cloud operating margin turning negative
Metrics to watch
- Google Cloud revenue growth and operating margin
- Search & Other advertising revenue growth
- Free cash flow normalization post-peak CapEx
September 2026 Equity Research Report: Top 5 Undervalued U.S. Stocks With Improving Fundamentals
1. Executive Summary
- Data Reference Date: September 4, 2026
- Total Candidates Screened: 12 U.S. Equities (S&P 500 / Russell 1000)
- Market Environment Overview: Heading into September 2026, U.S. equity markets exhibit widening performance dispersion. Despite broader macroeconomic uncertainties, select large-cap and mid-cap compounders are delivering solid revenue and operating margin (OPM) expansion alongside surging Free Cash Flow (FCF), yet trade at historically depressed multiples.
- Selection Criteria:
- Underperforming 3-month price momentum relative to the S&P 500
- Accelerating YoY revenue, operating profitability (OPM %p), or FCF generation in recent earnings
- Clean, resilient balance sheets with net cash or manageable debt maturities
- Noticeable valuation discount vs. 5-year historical medians and industry peers
- Clear, quantifiable catalysts expected within a 6–18 month horizon
2. Candidate Comparison Table
| Rank | Ticker | Company Name | Sector | 3M Return | Rev Growth YoY | OPM Change (%p) | FCF Status | Total Score |
|---|
| 1 | PYPL | PayPal Holdings, Inc. | Fintech / Payments | -12.5% | +10.0% | +1.2%p | TTM FCF $5.8B (+179% YoY Q2) | 88.0 |
| 2 | CVS | CVS Health Corporation | Healthcare Services / Pharmacy | -5.8% | +7.3% | +1.0%p | FY26 CFFO >=$11.5B (TTM FCF $8.3B) | 85.0 |
| 3 | ADSK | Autodesk, Inc. | Enterprise Software / Design | -4.2% | +16.0% | +2.0%p | FY27 FCF $2.74B (Q2 FCF $561M) | 84.0 |
| 4 | DIS | The Walt Disney Company | Entertainment / Streaming | -2.1% | +7.0% | +1.9%p | Q3 FCF $3.1B (+63% YoY) | 82.0 |
| 5 | GOOGL | Alphabet Inc. | Technology / Cloud & Ads | -14.8% | +24.2% | +2.0%p | TTM FCF $68.2B ($129B Net Cash) | 82.0 |
| 6 | BMY | Bristol-Myers Squibb | Healthcare / Biopharma | +18.2% | +6.0% | +3.2%p | TTM FCF $11.8B | 79.0 |
| 7 | UPS | United Parcel Service | Industrials / Logistics | -2.0% | +6.5% | +0.6%p | TTM FCF $4.8B | 77.5 |
| 8 | CRM | Salesforce, Inc. | Enterprise Cloud / CRM | +9.5% | +11.2% | +1.6%p | TTM FCF $12.8B (+22% YoY) | 76.5 |
| 9 | ADM | Archer-Daniels-Midland | Consumer Staples / Agribusiness | +1.9% | +7.2% | +2.5%p | TTM FCF $2.9B | 75.0 |
| 10 | NKE | Nike, Inc. | Consumer Discretionary / Footwear | -18.2% | -1.0% | +0.0%p | FY26 FCF $2.2B | 73.5 |
| 11 | SBUX | Starbucks Corporation | Consumer Discretionary / Restaurants | +12.4% | -1.0% | +4.3%p | TTM FCF $3.8B | 72.0 |
| 12 | AMGN | Amgen Inc. | Healthcare / Biotechnology | +27.6% | +10.0% | -0.5%p | Q2 FCF $3.5B (TTM FCF $10.5B) | 71.0 |
3. Final Top 5 Recommendations
1. PayPal Holdings, Inc. (NASDAQ: PYPL) — Score: 8.8 / 10
- Investment Thesis: Trading at just ~10.0x forward P/E despite delivering +10% YoY revenue expansion and a +179% surge in Q2 FCF. Management is utilizing robust organic cash flows to repurchase over 7% of shares outstanding annually, creating an EPS compounding flywheel that the market is severely underpricing.
- Core Catalysts:
- Fastlane guest checkout commercial scaling across global enterprise e-commerce platforms.
- Acceleration of Venmo monetization via debit card volume and merchant checkout adoption.
- $5.0B–$6.0B annual share repurchases providing steady high-single-digit EPS accretion.
- Key Risks:
- Heightened competition from native wallets (Apple Pay, Google Wallet) on mobile web.
- Transaction margin dollar mix pressure from unbranded processing expansion.
2. CVS Health Corporation (NYSE: CVS) — Score: 8.5 / 10
- Investment Thesis: Exceptional turnaround risk/reward trading at 11.7x forward earnings with a 2.7%+ dividend yield. Q2 results confirmed inflection with Medical Benefit Ratio (MBR) improving 250 bps YoY to 87.4%, alongside raised full-year cash flow guidance.
- Core Catalysts:
- Execution of Medicare Advantage margin recovery pathway through FY2027.
- Implementation of Aetna Claims Assist AI automation driving operational cost reductions.
- MinuteClinic care delivery and pharmacy foot-traffic expansion via GLP-1 therapy integration.
- Key Risks:
- Potential medical utilization spikes in Medicare Advantage during H2 2026.
- Ongoing legislative and regulatory scrutiny surrounding PBM rebate transparency.
3. Autodesk, Inc. (NASDAQ: ADSK) — Score: 8.4 / 10
- Investment Thesis: Mission-critical design and engineering software monopoly boasting 90%+ gross margins and 41% Non-GAAP operating margins. ADSK trades at a ~25% valuation discount to its 5-year average (~20.6x forward P/E) as the multi-year agency transition draws to completion.
- Core Catalysts:
- Full global deployment of direct agency New Transaction Model eliminating discounting friction.
- Monetization rollout of generative AI design agents across Autodesk Forma, Fusion, and Revit.
- Cross-selling operational workflow software following MaintainX integration.
- Key Risks:
- Temporary elongation of enterprise sales cycles during agency model transition.
- Macro cyclical softening in commercial building starts and infrastructure funding.
4. The Walt Disney Company (NYSE: DIS) — Score: 8.2 / 10
- Investment Thesis: Entertainment direct-to-consumer (DTC) streaming segment has successfully pivoted into sustainable profitability (+64% operating income improvement), complementing the high-barrier Experiences moat that generates over $10B in quarterly cash flows and funds $9B+ in share repurchases.
- Core Catalysts:
- Expansion of DTC streaming operating margins toward the 10%+ target range.
- Flagship ESPN standalone streaming platform rollout with expanded digital sports bundles.
- Execution of $9.0B+ share buyback program across FY2026.
- Key Risks:
- Accelerated cord-cutting outpacing streaming price increases in legacy linear networks.
- Discretionary spending headwinds impacting domestic theme park per-capita expenditures.
5. Alphabet Inc. (NASDAQ: GOOGL) — Score: 8.2 / 10
- Investment Thesis: Extreme mega-cap valuation dislocation at ~16.2x forward P/E against +24.2% consolidated revenue growth. Google Cloud is accelerating at +82% YoY with expanding operating margins, supported by $129.3B in net cash and aggressive AI TPU hardware efficiency.
- Core Catalysts:
- Regulatory clarity and search remedy settlement without structural corporate breakup.
- Gemini OS native integration driving higher AI search monetizable queries across Android/Workspace.
- Google Cloud margin expansion as internal TPU custom silicon lowers per-query inferencing costs.
- Key Risks:
- DOJ antitrust remedies impacting exclusive search default distribution contracts.
- Elevated infrastructure depreciation schedules resulting from intensive AI CapEx cycles.
4. Conclusion
- Highest Conviction Pick: PYPL (Best cash-flow yield and shareholder capital return setup)
- Best Risk/Reward: CVS (Structural healthcare insurance turnaround play)
- Most Defensive Pick: ADSK (High recurring subscription cash flows and software moat)
- Highest Rebound Potential: GOOGL (Depressed multiple vs. fundamentals due to legal overhang)
- Watchlist Candidate: NKE (Awaiting confirmation of inventory clearance and product cycle turnaround)
Not investment advice. Scores and lists are relative snapshots.
← All notes